Abstract
Recent advancements in profiling genomic and proteomic aberrations of circulating tumor cells (CTCs) have provided a greater understanding of the underlying biology of tumor dissemination and subsequent metastases. Unfortunately, cancer is a complex disease with cancer growth, progression, and spread all intricately dependent not only on cancer cells, but also on a variety of nonmalignant cell types that make up the cancer environment. The concept of a “liquid biopsy,” which has recently gained great traction in the field of cancer research, revolves around analyzing the proteomic and genomic characteristics of CTCs and circulating tumor debris (i.e., circulating tumor DNA, tumor exosomes). However, a key concern of this single focus is the loss of vital information provided by nonmalignant cancer-associated cells, i.e., circulating stromal cells and circulating immune cells. Even though non-cancer immune cells are required contributors to the malignant behavior of tumors and are in many cases “abnormal” themselves, why is their study in “liquid biopsies” largely ignored? In this new era of targeted cancer therapies, i.e., immunotherapies, which target tumor cells and stromal cells, diagnostics for personalized treatment requires the ability to effectively account for both pro-cancerous nonmalignant cells and malignant cells. Given that blood harbors several circulating tumor-derived cells, representing a circulating metastatic niche, we must reevaluate what defines a “blood-based biopsy”(BBB) beyond conventional liquid biopsies to include circulating stromal cells as potential diagnostic targets.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chen F, Zhuang X, Lin L, Yu P, Wang Y, Shi Y, Hu G, Sun Y (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13:45
Dvorak HF (1986) Tumors: wounds that do not heal. N Engl J Med 315(26):1650–1659
Fidler IJ (1970) Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 45(4):773–782
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol Mech Dis 1:119–150
Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275–292
Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, Williams AJ, Cote RJ, Lippman ME, Datar RH (2015) Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res 75(22):4681–4687
Beerepoot L, Mehra N, Vermaat J, Zonnenberg B, Gebbink M, Voest E (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1):139–145
Goon PK, Boos CJ, Stonelake PS, Blann AD, GY Lip (2006) Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 96(1):45
Kraan J, Sleijfer S, Foekens JA, Gratama JW (2012) Clinical value of circulating endothelial cell detection in oncology. Drug Discov Today 17(13–14):710–717
Leers MP, Nap M, Herwig R, Delaere K, Nauwelaers F (2008) Circulating PSA-containing macrophages as a possible target for the detection of prostate cancer: a three-color/five-parameter flow cytometric study on peripheral blood samples. Am J Clin Pathol 129(4):649–656
Masouleh BK, Baraniskin A, Schmiegel W, Schroers R (2010) Quantification of circulating endothelial progenitor cells in human peripheral blood: establishing a reliable flow cytometry protocol. J Immunol Methods 357(1):38–42
Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71–78
Schauer IG, Sood AK, Mok S, Liu J (2011) Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 13(5):393–405
Sone S, Key ME (1986) Antitumor and phagocytic activities of rat alveolar macrophage subpopulations separated on a discontinuous gradient of bovine serum albumin. J Biol Response Mod 5(6):595–603
De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S et al (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14(4):299–311
De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226
Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK (2010) Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 107(50):21677–21682
Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A (2016) Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut 65(6):990–1000
Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian B-Z, Oktay MH, Pollard JW, Jones JG, Condeelis JS (2015) Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage–derived VEGFA. Cancer Discov 5(9):932–943
Szulczewski JM, Inman DR, Entenberg D, Ponik SM, Aguirre-Ghiso J, Castracane J, Condeelis J, Eliceiri KW, Keely PJ (2016) In vivo visualization of stromal macrophages via label-free FLIM-based metabolite imaging. Sci Rep 6:25086
Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49–61
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373(17):1627–1639
Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135
Callahan MK, Ott PA, Odunsi K, Bertolini SV, Pan LS, Venhaus RR, Karakunnel JJ, Hodi FS, Wolchok JD (2014) A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. In: ASCO Annual Meeting Proceedings 2014:TPS3120
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16(3):257–265
Rosenberg SA (2014) Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment. Nat Rev Clin Oncol 11(11):630–632
Sundar R, Cho B-C, Brahmer JR, Soo RA (2015) Nivolumab in NSCLC: latest evidence and clinical potential. Therapeutic Adv Med Oncol 7(2):85–96
Adams DL, Edelman MJ, Fang P, Jiang W, He J, Xu T, Gao H, Reuben JM, Qiao Y, Hahn S, Lin S (2016) Sequential tracking of PD-L1 expression and RAD50 induction in CTCs and circulating stromal cells of lung cancer patients during treatment with radiotherapy. Cancer Res 76(14 Supplement):4990–4990
Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1(9):1325–1332
Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US (2015) Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses–pre-clinical evidence and ongoing clinical applications. Front Immunol 6:505
Lin SH, He J, Edelman M, Xu T, Gao H, Reuben J, Qiao Y, Liu H, Amstutz P, Hahn S, Adams DL (2015) Sequential assessment of DNA damage response and PD-L1 expression in circulating tumor cells of lung cancer patients during Radiotherapy. J Thorac Oncol:S266–S267
Ma W, Gilligan BM, Yuan J, Li T (2016) Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 9(1):1
Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK (2015) Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch((R)) CTC test. Cytometry A 87(2):137–144
Adams DL, Zhu P, Makarova OV, Martin SS, Charpentier M, Chumsri S, Li S, Amstutz P, Tang CM (2014) The systematic study of circulating tumor cell isolation using lithographic microfilters. RSC Adv 9:4334–4342
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904
Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP et al (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6(2):125–132
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(19):3213–3221
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791
Danila DC, Fleisher M, Scher HI (2011) Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17(12):3903–3912
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309
Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D et al (2011) A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105(6):847–853
Ferreira MM, Ramani VC, Jeffrey SS (2016) Circulating Tumor Cell Technologies. Mol Oncol 10(3):374–394
Kagan M, Howard D, Bendele T, Mayes J, Silvia J, Repollet M, Doyle J, Allard J, Tu N, Bui T et al (2002) A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 25(1):104–110
Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C (2014) Molecular analysis of circulating tumour cells [mdash] biology and biomarkers. Nat Rev Clin Oncol 11(3):129–144
Lianidou ES, Markou A (2011) Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 57(9):1242–1255
Lianidou ES, Markou A (2011) Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clin Chem Lab Med 49(10):1579–1590
MassardC, OulhenM, Le MoulecS, AugerN, FoulonS, Abou-LovergneA, BilliotF, ValentA, MartyV, LoriotY (2016) Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study. Oncotarget
O’Flaherty JD, Gray S, Richard D, Fennell D, O’Leary JJ, Blackhall FH, O’Byrne KJ (2012) Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 76(1):19–25
Paoletti C, Muniz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL et al (2015) Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res 21(11):2487–2498
Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180–204
Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS et al (2010) Molecular biomarker analyses using circulating tumor cells. PLoS One 5(9):e12517
Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z et al (2010) Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2(25):25ra23
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584
Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192(3):373–382
Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW (2010) All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 21(9):1851–1857
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567
Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, Hoon DS, Kopetz ES (2015) Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 10(10):e0140712
Stefansson S, Adams DL, Tang C-M (2013) Isolation of Low Abundance Proteins and Cells Using Buoyant Glass Microbubble Chromatography. Chromatogr Res Int 2013:1–6
Volik S, Alcaide M, Morin RD, Collins CC (2016) Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res 4(10):898–908
Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA (2014) Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer cell 26(5):707–721
Webber J, Steadman R, Mason MD, Tabi Z, Clayton A (2010) Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 70(23):9621–9630
Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR (2016) Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol Biomark Prev 25(7):1037–1042
Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM et al (2014) Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111(9):3514–3519
Bethel K, Luttgen MS, Damani S, Kolatkar A, Lamy R, Sabouri-Ghomi M, Topol S, Topol EJ, Kuhn P (2014) Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Phys Biol 11(1):016002
Cima I, Kong SL, Sengupta D, Tan IB, Phyo WM, Lee D, Hu M, Iliescu C, Alexander I, Goh WL et al (2016) Tumor-derived circulating endothelial cell clusters in colorectal cancer. Sci Transl Med 8(345):345ra389
Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431–446
Ishii G, Ito TK, Aoyagi K, Fujimoto H, Chiba H, Hasebe T, Fujii S, Nagai K, Sasaki H, Ochiai A (2007) Presence of human circulating progenitor cells for cancer stromal fibroblasts in the blood of lung cancer patients. Stem Cells 25(6):1469–1477
Japink D, Leers MP, Sosef MN, Nap M (2009) CEA in activated macrophages. New diagnostic possibilities for tumor markers in early colorectal cancer. Anticancer Res 29(8):3245–3251
Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH (2013) Circulating fibroblast-like cells in men with metastatic prostate cancer. Prostate 73(2):176–181
Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71(2):105–113
Strijbos M, Gratama J-W, Kraan J, Lamers C, Den Bakker M, Sleijfer S (2008) Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 98(11):1731–1735
Adams D, Alpaugh RK, Cristofanilli M, Martin S, Chumsri S, Charpentier M, Bergan RC, Ogden IM, Tsai S, Zhu P (2013) Identifying and subtyping circulating tumor cells from breast, prostate, and pancreatic cancer patients based on distinct morphology. Cancer Res 73(8 Supplement):1448–1448
Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK (2016) Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. Breast Cancer Res BCR 18(1):44
Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Adams DK, Makarova OV, Zhu P, Li S et al (2016) Precision microfilters as an all in one system for multiplex analysis of circulating tumor cells. RSC Adv 6(8):6405–6414
Adams DL, Alpaugh RK, Tsai S, Tang CM, Stefansson S (2016) Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. Sci Rep 6:33488
El-Heliebi A, Kroneis T, Zohrer E, Haybaeck J, Fischereder K, Kampel-Kettner K, Zigeuner R, Pock H, Riedl R, Stauber R et al (2013) Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer? J Transl Med 11:214
Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J, Sidhu H, Uzgiris A et al (2015) A Novel Strategy for Detection and Enumeration of Circulating Rare Cell Populations in Metastatic Cancer Patients Using Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One 10(10):e0141166
Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M et al (2009) Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15(6):2091–2097
Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R et al (2014) Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32(5):479–484
Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B et al (2014) Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med 6(11):1371–1386
Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA et al (2012) Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7(5):e33788
Cima I, Wen Yee C, Iliescu FS, Phyo WM, Lim KH, Iliescu C, Tan MH (2013) Label-free isolation of circulating tumor cells in microfluidic devices: Current research and perspectives. Biomicrofluidics 7(1):11810
Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, Scadden DT, Wagner DD (2012) Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci 109(32):13076–13081
Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N (2011) Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One 6(10):e26125
Hume R, West JT, Malmgren RA, Chu EA (1964) Quantitative observations of circulating megakaryocytes in the blood of patients with cancer. N Engl J Med 270(3):111–117
Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, Verhoef C, Sleijfer S, Gratama JW (2012) A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 10(5):931–939
Adams DL, Makarova O, Zhu P, Li S, Amstutz P, Tang C (2011) Isolation of circulating tumor cells by size exclusion using lithography fabricated precision microfilters. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research Cancer Res 71(8):2369
Vona G, Estepa L, Beroud C, Damotte D, Capron F, Nalpas B, Mineur A, Franco D, Lacour B, Pol S et al (2004) Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39(3):792–797
Adams D, Makarova O, Zu P, (2011) Isolation of circulating tumor cells by size exclusion using lithography fabricated precision microfilters. Proceedings 102nd AACR Meeting 71(8 supplement 2369–2369)
Adams D, Martin S, Chumsri S, Charpentier M, Alpaugh R, Cristofanilli M, Tang C, Haudenschild C (2015) Applying a mitotic index to circulating tumor cells and its prognostic significance: A cytological approach to patient stratification. J Clin Oncol 33:11029 ASCO Annual Meeting Proceedings
Adams D, Tsai S, Makarova OV, Zhu P, Li S, Amstutz PT, Tang C-M (2013) Low cytokeratin-and low EpCAM-expressing circulating tumor cells in pancreatic cancer. J Clin Oncol 31:11046 ASCO Annual Meeting Proceedings
Adams D, Zhu P, Makarova O, Li S, Amstutz P, Tang C (2012) HER-2 FISH analysis and H & E staining of circulating tumor cells pre-isolated using high porosity precision microfilters. Cancer Res 72(8 Supplement):2395–2395
Adams DL, Bergan RC, Martin SS, Chumsri S, Charpentier M, Lapidus RG, Alpaugh RK, Cristofanilli M, Tsai S, Tang C-M (2015) Correlation of cancer-associated macrophage-like cells with systemic therapy and pathological stage in numerous malignancies. J Clin Oncol 2015:11095 ASCO Annual Meeting Proceedings
Coumans FA, van Dalum G, Beck M, Terstappen LW (2013) Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One 8(4):e61770
Hosokawa M, Hayata T, Fukuda Y, Arakaki A, Yoshino T, Tanaka T, Matsunaga T (2010) Size-selective microcavity array for rapid and efficient detection of circulating tumor cells. Anal Chem 82(15):6629–6635
LimLS, HuM, HuangMC, CheongWC, GanAT, LooiXL, LeongSM, Koay ES, Li MH: Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab Chip2012.
Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC et al (2010) Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16(20):5011–5018
Makarova OV, Adams DL, Divan R, Rosenmann D, Zhu P, Li S, Amstutz P, Tang CM (2016) Polymer microfilters with nanostructured surfaces for the culture of circulating cancer cells. Mater Sci Eng C 66:193–198
Stefansson S, Adams DL, Ershler WB, Le H, Ho DH (2016) A cell transportation solution that preserves live circulating tumor cells in patient blood samples. BMC Cancer 16(1):300
Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ, Tai YC (2007) Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr 1162(2):154–161
Zhu P, Stanton ML, Castle EP, Joseph RW, Adams DL, Li S, Amstutz P, Tang CM, Ho TH (2016) Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. J Transl Med 14(1):198
Seal SH (1964) A Sieve for the Isolation of Cancer Cells and Other Large Cells from the Blood. Cancer 17:637–642
Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A et al (2012) Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol 7(2):306–315
Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 97(26):14608–14613
Damani S, Bacconi A, Libiger O, Chourasia AH, Serry R, Gollapudi R, Goldberg R, Rapeport K, Haaser S, Topol S et al (2012) Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med 4(126):126ra133
Tuting T, de Visser KE (2016) CANCER. How neutrophils promote metastasis. Science 352(6282):145–146
Ghosh S, Hughes D, Parma DL, Ramirez A, Li R (2014) Association of obesity and circulating adipose stromal cells among breast cancer survivors. Mol Biol Rep 41(5):2907–2916
Alix-Panabières C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59(1):110–118
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10(8):472–484
Diaz LA, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32(6):579–586
Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371(26):2477–2487
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488–2498
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM et al (2015) Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348(6237):880–886
Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20(12):1472–1478
Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64(22):8249–8255
Hill R, Song Y, Cardiff RD, Van Dyke T (2005) Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123(6):1001–1011
Houghton J, Li H, Fan X, Liu Y, Liu JH, Rao VP, Poutahidis T, Taylor CL, Jackson EA, Hewes C et al (2010) Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev 19(8):1153–1166
Iguchi Y, Ito YM, Kataoka F, Nomura H, Tanaka H, Chiyoda T, Hashimoto S, Nishimura S, Takano M, Yamagami W et al (2014) Simultaneous analysis of the gene expression profiles of cancer and stromal cells in endometrial cancer. Genes Chromosomes Cancer 53(9):725–737
Kinseth MA, Jia Z, Rahmatpanah F, Sawyers A, Sutton M, Wang-Rodriguez J, Mercola D, McGuire KL (2014) Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes. Int J Cancer 134(1):81–91
Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 357(25):2543–2551
Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824–828
Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B et al (2015) High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann Oncol 26(7):1408–1415
Acknowledgements
We would like to thank all of the patients and all of the healthy volunteers who contributed to this study. We also thank Drs. S. Stefansson, D.K. Adams, and C.M. Tang for the help in editing this chapter. This work was supported by the US Army Research Office (ARO) and the Defense Advanced Research Projects Agency (DARPA) (W911NF-14-C0098). The content of the information does not necessarily reflect the position or the policy of the US Government.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Adams, D.L., Cristofanilli, M. (2017). Detecting and Monitoring Circulating Stromal Cells from Solid Tumors Using Blood-Based Biopsies in the Twenty-First Century: Have Circulating Stromal Cells Come of Age?. In: Cristofanilli, M. (eds) Liquid Biopsies in Solid Tumors. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-50956-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-50956-3_5
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-50955-6
Online ISBN: 978-3-319-50956-3
eBook Packages: MedicineMedicine (R0)